Seres Therapeutics, Inc.
MCRB
$16.70
-$0.64-3.69%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 351.00K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 351.00K | -- | -- | -- | -- |
| Cost of Revenue | 1.81M | 14.63M | 3.53M | 5.13M | 2.96M |
| Gross Profit | -1.46M | -14.63M | -3.53M | -5.13M | -2.96M |
| SG&A Expenses | 9.48M | 10.25M | 11.89M | 12.46M | 12.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.83M | 24.88M | 27.24M | 28.84M | 29.17M |
| Operating Income | -22.48M | -24.88M | -27.24M | -28.84M | -29.17M |
| Income Before Tax | 8.20M | -19.86M | 32.68M | -15.64M | -51.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.20M | -19.86M | 32.68M | -15.64M | -51.04M |
| Earnings from Discontinued Operations | -- | -- | -- | 0.00 | 139.81M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.20M | -19.86M | 32.68M | -15.64M | 88.78M |
| EBIT | -22.48M | -24.88M | -27.24M | -28.84M | -29.17M |
| EBITDA | -21.43M | -23.82M | -26.16M | -27.75M | -27.77M |
| EPS Basic | 0.94 | -2.27 | 3.76 | -1.83 | 11.63 |
| Normalized Basic EPS | -1.36 | -1.43 | -1.40 | 0.15 | -4.18 |
| EPS Diluted | 0.94 | -2.27 | 3.75 | -1.89 | 11.63 |
| Normalized Diluted EPS | -1.36 | -1.43 | -1.40 | 0.15 | -4.18 |
| Average Basic Shares Outstanding | 8.76M | 8.74M | 8.70M | 8.57M | 7.63M |
| Average Diluted Shares Outstanding | 8.77M | 8.74M | 8.71M | 8.57M | 7.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |